VHT - Vanguard Health Care ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
174.10
-0.50 (-0.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close174.60
Open174.36
Bid0.00 x 800
Ask0.00 x 800
Day's Range174.04 - 174.85
52 Week Range148.31 - 181.92
Volume383,409
Avg. Volume371,961
Net Assets10.31B
NAV174.62
PE Ratio (TTM)72.09
Yield1.31%
YTD Return7.19%
Beta (3Y Monthly)0.98
Expense Ratio (net)0.10%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • U.S.-China Trade Talks Begin: 5 Safe ETFs to Follow
    Zacks21 days ago

    U.S.-China Trade Talks Begin: 5 Safe ETFs to Follow

    The U.S.-China trade talks start today but chances of a definite deal are low. Investors can thus bet on these safe ETFs.

  • What Analysts Recommend for Johnson & Johnson after Q4 Results
    Market Realist21 days ago

    What Analysts Recommend for Johnson & Johnson after Q4 Results

    Is Johnson & Johnson an Attractive Buy after Q4 Results?Stock price movementsOn January 28, Johnson & Johnson (JNJ) closed at $128.99, which is 0.63% higher than its previous closing price. The company closed at a premium of 8.74% as

  • Healthcare ETFs in Focus Ahead of Q4 Earnings
    Zacks27 days ago

    Healthcare ETFs in Focus Ahead of Q4 Earnings

    With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.

  • JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus
    Zacks28 days ago

    JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus

    Johnson & Johnson expects its sales growth to slow down this year due to pricing pressures and generic-drug competition for its pharmaceutical division. This has put healthcare ETFs in focus.

  • MarketWatch28 days ago

    Abbott stock falls 2.7% after fourth-quarter revenue falls short

    Shares of Abbott Laboratories fell 2.7% in premarket trade Wednesday after the company reported fourth-quarter results that met earnings expectations but fell short on revenue. Profit for the latest quarter rose to $654 million, or 37 cents a share, after a loss of $828 million, or a loss of 48 cents a share in the year-earlier quarter. Adjusted EPS was 81 cents a share, matching the FactSet consensus. Revenue was $7.765 billion, falling short of the FactSet consensus of $7.815 billion, but up from $7.589 one year ago. Revenue from Abbott's nutrition segment fell 0.4% to $1.777 billion, while revenue from its diagnostics segment rose 2.9% to $1.961 billion. Its established pharmaceuticals segment brought in $1.09 billion, down 4.8% from the year earlier, and revenue for Abbott's medical devices segment rose 6.7% to $2.92 billion. The company expects EPS of 25 cents to 27 cents for the first quarter of 2019, and full-year adjusted EPS of $3.15 to $3.25. The company also announced an 14% increase in quarterly dividend to 32 cents per share from 28 cents per share. Shares of Abbott have fallen 1.2% in the year to date through Tuesday, while the S&P 500 has gained 5%. The Vanguard Health Care ETF has gained 4.3%.

  • UnitedHealth Pops on Solid Q4: Healthcare ETFs to Buy
    Zackslast month

    UnitedHealth Pops on Solid Q4: Healthcare ETFs to Buy

    ETFs having the largest allocation to UnitedHealth has been in focus post its solid result.

  • How to Invest Like Jeff Bezos: The Top Three Sectors to Watch
    Market Realistlast month

    How to Invest Like Jeff Bezos: The Top Three Sectors to Watch

    How to Invest Like Jeff Bezos: The Top Three Sectors to WatchJeff Bezos’s investmentsJeff Bezos, Amazon’s (AMZN) founder and CEO, topped Forbes’s list of the world’s billionaires in 2018. According to the list, he had $112 billion in

  • What Are Analysts Recommending for Mylan in January?
    Market Realistlast month

    What Are Analysts Recommending for Mylan in January?

    Teva or Mylan: Which Is the Better Generic Play in January? (Continued from Prior Part) ## MYL’s price movements On January 8, Mylan (MYL) closed at $29.87, up 0.40% from its previous closing price. The company closed at a premium of 14.73% to its 52-week low price of $26.03 and at a discount of 37.54% to its 52-week high price of $47.82. As of January 8, Mylan’s market cap is $15.37 billion. The company is trading at a trailing PE ratio of 24.13x and a forward PE ratio of 5.85x. Based on its closing price on January 8, the company had reported returns of 9.01% in the last week, -6.19% in the last month, and -15.36% in the last quarter. It had also reported returns of -19.51% in the last half year, -32.94% in the last year, and 9.01% YTD (year-to-date). Based on its closing price on January 7, the US healthcare sector represented by the Vanguard Health Care ETF (VHT) had reported returns of 1.47% in the last week, -6.03% in the last month, and -8.31% in the last quarter. VHT had also reported returns of -1.45% in the last half year, 2.56% in the last year, and 1.47% YTD. ## Analysts’ recommendations and target prices for Mylan The 12-month consensus analyst recommendation for Mylan as of January 9 is a “buy.” The 12-month consensus target price for the company is $42.63, 42.72% higher than its closing price on January 8. The highest target price estimate for the company is $55, and the lowest target price estimate is $28. Of the 17 analysts covering Mylan on January 9, seven analysts have rated the company as a “strong buy,” six have rated it as a “buy,” and four have rated it as a “hold.” In the next article, we’ll compare the revenue growth prospects of Teva Pharmaceutical and Mylan in greater detail. Continue to Next Part Browse this series on Market Realist: * Part 1 - What Analysts Are Recommending for Teva Pharmaceutical in January * Part 3 - Teva or Mylan: Who Has the More Promising Revenue Trajectory? * Part 4 - Teva or Mylan: Whose Earnings Are Growing Faster?

  • Three Healthcare Stocks Rallying Over 10% Today
    Market Realistlast month

    Three Healthcare Stocks Rallying Over 10% Today

    Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.

  • ETF Trends2 months ago

    Some Value Remains With HealthCare ETFs

    Compared to other sectors, healthcare was sturdy in 2018 and while the sector looks close to being fairly valued, the group could offer more upside this year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.

  • Best Sector of 2018 and its Hit ETFs & Stocks
    Zacks2 months ago

    Best Sector of 2018 and its Hit ETFs & Stocks

    Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.

  • Investment Options That Can Help Millennials Shed Risk Aversion
    Zacks2 months ago

    Investment Options That Can Help Millennials Shed Risk Aversion

    While millennials are doing a good job of saving in traditional ways, not parking their money in high-return investment options could be a potential mistake.

  • ETF Trends3 months ago

    10 Sector ETFs That Could Stand Out in the New Year

    The U.S. equity rally is beginning to lose steam and investors should not expect markets to maintain their breakneck spurt of yesteryear. Nevertheless, traders may still find value in some battered sectors ...

  • ETF Trends3 months ago

    Stable, Defensive Sector ETFs for a Wobbly Market

    As U.S. markets continue to wobble, investors who want to stay in the game can look to defensive sector-related ETFs for a more steady approach. “If the sell-off continues and it deepens, it’s going to ...

  • ETF Trends3 months ago

    Leveraged Healthcare ETF Gains On Midterm Election Results

    Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...

  • Top-Ranked Healthcare ETFs for Long-Term Investors
    Zacks4 months ago

    Top-Ranked Healthcare ETFs for Long-Term Investors

    Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.

  • ETF Trends4 months ago

    Health Care ETFs Retreat on DOJ Approval of Aetna-CVS Merger

    The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.

  • Zacks5 months ago

    Dow Closes at Another New High

    Dow Closes at Another New High

  • Investopedia5 months ago

    Why Stock Market's 'Out of Whack' Leadership Signals Next Crash

    Defensive stocks are market leaders, and that signals big trouble ahead, per Jim Paulsen of The Leuthold Group.